Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
The Ratify Effect on Event-Free Survival
The Grall study did show an improvement in EFS. But numerically, there's a big difference though, right? I know it didn't mean statistical significance and perhaps they thought their event rate was going to be higher. If you added more tux maps throughout therapy, would you have improved outcomes further? And maybe it would be statistically better? Maybe but at the end of the day,. There's a teeny, tiny numerical difference in EFS and no difference in OS in this study.
Transcript
Play full episode
